Engimmune Therapeutics

Engineering Precision Immunotherapy

Founded 2021 · $19.3M raised

Employees
11–50
Founded
2021
Business Model
B2B
Total Funding
$19.3M
Last Round
$19.3M SeedMay 2022
Rounds
1

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

About

Engimmune Therapeutics develops targeted, highly potent off-the-shelf soluble T-cell receptor drugs to treat solid tumour cancers. Founded in 2021 and led by veteran biotherapeutics developers and protein engineers, the company couples AI-guided innovation with laboratory insights to unlock soluble TCR engagers. Its foundational technology is based on inventions by Dr. Rodrigo Vazquez-Lombardi and Prof. Sai Reddy. After a seed round co-led by Pureos Bioventures and Novo Holdings, Engimmune built a differentiated pipeline of soluble TCR therapeutics.

Summary

Engimmune Therapeutics is an Artificial Intelligence company, founded in 2021. It has raised $19.3M in total across 1 round, most recently a $19.3M Seed round in May 2022. Investors include BB Pureos and Novo Holdings A/S.

Tech & App Stack

4 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

SeedSeed RoundMay 2022
$19.3M

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Engimmune Therapeutics on Indexed.vc
<a href="https://indexed.vc/companies/engimmune-therapeutics"><img src="https://indexed.vc/api/badge/company/engimmune-therapeutics" alt="Engimmune Therapeutics on Indexed.vc" width="260" height="76" /></a>